Option Care Health (OPCH)
NASDAQ:OPCH
US Market
Advertisement

Option Care Health (OPCH) Stock Forecast & Price Target

Compare
538 Followers
See the Price Targets and Ratings of:

OPCH Analyst Ratings

Strong Buy
8Ratings
Strong Buy
7 Buy
1 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Option
Care Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

OPCH Stock 12 Month Forecast

Average Price Target

$36.43
▲(28.23% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Option Care Health in the last 3 months. The average price target is $36.43 with a high forecast of $40.00 and a low forecast of $27.00. The average price target represents a 28.23% change from the last price of $28.41.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"22":"$22","41":"$41","26.75":"$26.8","31.5":"$31.5","36.25":"$36.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36.43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$36.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$27.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[22,26.75,31.5,36.25,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.03,27.104615384615386,28.17923076923077,29.253846153846155,30.32846153846154,31.403076923076924,32.47769230769231,33.55230769230769,34.62692307692308,35.70153846153846,36.776153846153846,37.85076923076923,38.925384615384615,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.03,26.830000000000002,27.630000000000003,28.43,29.23,30.03,30.830000000000002,31.630000000000003,32.43,33.230000000000004,34.03,34.83,35.63,{"y":36.43,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.03,26.104615384615386,26.17923076923077,26.253846153846155,26.32846153846154,26.403076923076924,26.47769230769231,26.552307692307693,26.626923076923077,26.701538461538462,26.776153846153846,26.85076923076923,26.925384615384615,{"y":27,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.11,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.12,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.2,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.92,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.95,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.17,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.86,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.95,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.26,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.44,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.24,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.03,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$40.00Average Price Target$36.43Lowest Price Target$27.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TR | OpenAI - 4o Analyst forecast on OPCH
TR | OpenAI - 4o
TR | OpenAI - 4o
$28$31
Hold
9.12%
Upside
Reiterated
11/12/25
AI Generated ArticleAI Generated Article
J.P. Morgan Analyst forecast on OPCH
J.P. Morgan
J.P. Morgan
$39
Buy
37.28%
Upside
Reiterated
11/07/25
Option Care Health (OPCH) Gets a Buy from J.P. Morgan
Truist Financial Analyst forecast on OPCH
Truist Financial
Truist Financial
$40
Buy
40.80%
Upside
Reiterated
11/06/25
Option Care Health (OPCH) Gets a Buy from Truist Financial
TD Cowen
$30$27
Hold
-4.96%
Downside
Reiterated
11/03/25
Option Care Health price target lowered to $27 from $30 at TD CowenOption Care Health price target lowered to $27 from $30 at TD Cowen
Barrington Analyst forecast on OPCH
Barrington
Barrington
$38
Buy
33.76%
Upside
Reiterated
10/31/25
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD) and Option Care Health (NASDAQ: OPCH)We are maintaining our OUTPERFORM investment rating on OPCH and our price target remains $38. We arrive at our price target by attaching a 13.5x multiple to our 2026 adjusted EBITDA estimate.
Citizens JMP
$36
Buy
26.72%
Upside
Reiterated
10/31/25
Citizens JMP Remains a Buy on Option Care Health (OPCH)
William Blair Analyst forecast on OPCH
William Blair
William Blair
Buy
Reiterated
10/30/25
Option Care Health: Strong Financial Performance and Strategic Positioning Justify Buy RatingWe will update our model and estimates after the conference call. Care delivered results ahead of expectations for the 23rd straight quarter, with revenue, adjusted EBITDA, and adjusted EPS all beating our/Street estimates. Management again raised its full-year guidance and now expects revenue of $5.60 billion to $5.65 billion (up from $5.50 billion to $5.65 billion), adjusted EBITDA of $468 million to $473 million (narrowed from $465 million to $475 million), adjusted EPS of $1.68 to $1.72 (up from $1.65 to $1.72), and operating cash flow of at least $320 million (unchanged). On balance, this looks to be another solid update for Option Care amid the ongoing Stelara headwind, which we look to the call for an update on (previously guided to a $60 million to $70 million gross profit impact in 2025).
Morgan Stanley Analyst forecast on OPCH
Morgan Stanley
Morgan Stanley
$35
Buy
23.20%
Upside
Initiated
10/17/25
Option Care Health: Positioned for Growth in the Expanding Infusion Market
UBS
$40
Buy
40.80%
Upside
Reiterated
09/23/25
Option Care Health (OPCH) Receives a Buy from UBSUBS analyst AJ Rice reiterated a Buy rating and $40.00 price target on Option Care Health (NASDAQ: OPCH).
Bank of America Securities Analyst forecast on OPCH
Bank of America Securities
Bank of America Securities
Buy
Reiterated
05/14/25
Bank of America Securities Remains a Buy on Option Care Health (OPCH)
Jefferies
$40
Buy
40.80%
Upside
Reiterated
04/11/25
Minimal Impact of VYVGART Approval on Option Care Health Justifies Buy Rating
Goldman Sachs Analyst forecast on OPCH
Goldman Sachs
Goldman Sachs
$25$35
Hold
23.20%
Upside
Reiterated
02/28/25
Option Care Health (OPCH) PT Raised to $35 at Goldman SachsGoldman Sachs analyst Jamie Perse raised the price target on Option Care Health (NASDAQ: OPCH) to $35.00 (from $25.00) while maintaining a Neutral rating.
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TR | OpenAI - 4o Analyst forecast on OPCH
TR | OpenAI - 4o
TR | OpenAI - 4o
$28$31
Hold
9.12%
Upside
Reiterated
11/12/25
AI Generated ArticleAI Generated Article
J.P. Morgan Analyst forecast on OPCH
J.P. Morgan
J.P. Morgan
$39
Buy
37.28%
Upside
Reiterated
11/07/25
Option Care Health (OPCH) Gets a Buy from J.P. Morgan
Truist Financial Analyst forecast on OPCH
Truist Financial
Truist Financial
$40
Buy
40.80%
Upside
Reiterated
11/06/25
Option Care Health (OPCH) Gets a Buy from Truist Financial
TD Cowen
$30$27
Hold
-4.96%
Downside
Reiterated
11/03/25
Option Care Health price target lowered to $27 from $30 at TD CowenOption Care Health price target lowered to $27 from $30 at TD Cowen
Barrington Analyst forecast on OPCH
Barrington
Barrington
$38
Buy
33.76%
Upside
Reiterated
10/31/25
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD) and Option Care Health (NASDAQ: OPCH)We are maintaining our OUTPERFORM investment rating on OPCH and our price target remains $38. We arrive at our price target by attaching a 13.5x multiple to our 2026 adjusted EBITDA estimate.
Citizens JMP
$36
Buy
26.72%
Upside
Reiterated
10/31/25
Citizens JMP Remains a Buy on Option Care Health (OPCH)
William Blair Analyst forecast on OPCH
William Blair
William Blair
Buy
Reiterated
10/30/25
Option Care Health: Strong Financial Performance and Strategic Positioning Justify Buy RatingWe will update our model and estimates after the conference call. Care delivered results ahead of expectations for the 23rd straight quarter, with revenue, adjusted EBITDA, and adjusted EPS all beating our/Street estimates. Management again raised its full-year guidance and now expects revenue of $5.60 billion to $5.65 billion (up from $5.50 billion to $5.65 billion), adjusted EBITDA of $468 million to $473 million (narrowed from $465 million to $475 million), adjusted EPS of $1.68 to $1.72 (up from $1.65 to $1.72), and operating cash flow of at least $320 million (unchanged). On balance, this looks to be another solid update for Option Care amid the ongoing Stelara headwind, which we look to the call for an update on (previously guided to a $60 million to $70 million gross profit impact in 2025).
Morgan Stanley Analyst forecast on OPCH
Morgan Stanley
Morgan Stanley
$35
Buy
23.20%
Upside
Initiated
10/17/25
Option Care Health: Positioned for Growth in the Expanding Infusion Market
UBS
$40
Buy
40.80%
Upside
Reiterated
09/23/25
Option Care Health (OPCH) Receives a Buy from UBSUBS analyst AJ Rice reiterated a Buy rating and $40.00 price target on Option Care Health (NASDAQ: OPCH).
Bank of America Securities Analyst forecast on OPCH
Bank of America Securities
Bank of America Securities
Buy
Reiterated
05/14/25
Bank of America Securities Remains a Buy on Option Care Health (OPCH)
Jefferies
$40
Buy
40.80%
Upside
Reiterated
04/11/25
Minimal Impact of VYVGART Approval on Option Care Health Justifies Buy Rating
Goldman Sachs Analyst forecast on OPCH
Goldman Sachs
Goldman Sachs
$25$35
Hold
23.20%
Upside
Reiterated
02/28/25
Option Care Health (OPCH) PT Raised to $35 at Goldman SachsGoldman Sachs analyst Jamie Perse raised the price target on Option Care Health (NASDAQ: OPCH) to $35.00 (from $25.00) while maintaining a Neutral rating.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Option Care Health

1 Month
xxx
Success Rate
20/29 ratings generated profit
69%
Average Return
+2.69%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 68.97% of your transactions generating a profit, with an average return of +2.69% per trade.
3 Months
xxx
Success Rate
15/29 ratings generated profit
52%
Average Return
+2.74%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 51.72% of your transactions generating a profit, with an average return of +2.74% per trade.
1 Year
David S MacdonaldTruist Financial
Success Rate
20/29 ratings generated profit
69%
Average Return
+8.14%
reiterated a buy rating 11 days ago
Copying David S Macdonald's trades and holding each position for 1 Year would result in 68.97% of your transactions generating a profit, with an average return of +8.14% per trade.
2 Years
xxx
Success Rate
23/36 ratings generated profit
64%
Average Return
+22.41%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 63.89% of your transactions generating a profit, with an average return of +22.41% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

OPCH Analyst Recommendation Trends

Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
0
0
0
1
1
Buy
24
19
17
13
12
Hold
0
1
3
5
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
24
20
20
19
19
In the current month, OPCH has received 13 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. OPCH average Analyst price target in the past 3 months is 36.43.
Each month's total comprises the sum of three months' worth of ratings.

OPCH Financial Forecast

OPCH Earnings Forecast

Next quarter’s earnings estimate for OPCH is $0.46 with a range of $0.45 to $0.48. The previous quarter’s EPS was $0.45. OPCH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year OPCH has Performed in-line its overall industry.
Next quarter’s earnings estimate for OPCH is $0.46 with a range of $0.45 to $0.48. The previous quarter’s EPS was $0.45. OPCH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year OPCH has Performed in-line its overall industry.

OPCH Sales Forecast

Next quarter’s sales forecast for OPCH is $1.46B with a range of $1.44B to $1.46B. The previous quarter’s sales results were $1.44B. OPCH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year OPCH has Performed in-line its overall industry.
Next quarter’s sales forecast for OPCH is $1.46B with a range of $1.44B to $1.46B. The previous quarter’s sales results were $1.44B. OPCH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year OPCH has Performed in-line its overall industry.

OPCH Stock Forecast FAQ

What is OPCH’s average 12-month price target, according to analysts?
Based on analyst ratings, Option Care Health’s 12-month average price target is 36.43.
    What is OPCH’s upside potential, based on the analysts’ average price target?
    Option Care Health has 28.23% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is OPCH a Buy, Sell or Hold?
          Option Care Health has a consensus rating of Strong Buy which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Option Care Health’s price target?
            The average price target for Option Care Health is 36.43. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $40.00 ,the lowest forecast is $27.00. The average price target represents 28.23% Increase from the current price of $28.41.
              What do analysts say about Option Care Health?
              Option Care Health’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of OPCH?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis